|
1
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: A clinical review. JAMA. 310:1842–1850.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vigneswaran K, Neill S and Hadjipanayis
CG: Beyond the World Health Organization grading of infiltrating
gliomas: Advances in the molecular genetics of glioma
classification. Ann Transl Med. 3:952015.PubMed/NCBI
|
|
3
|
Lou M and Zhao Y: Satisfactory therapy
results of combining nimustine with nicardipine against glioma at
advanced stage. J Cancer Res Ther. 11:10302015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li BO, Meng C, Zhang X, Cong D, Gao X, Gao
W, Ju D and Hu S: Effect of photodynamic therapy combined with
torasemide on the expression of matrix metalloproteinase 2 and
sodium-potassium-chloride cotransporter 1 in rat peritumoral edema
and glioma. Oncol Lett. 11:2084–2090. 2016.PubMed/NCBI
|
|
5
|
Paw I, Carpenter RC, Watabe K, Debinski W
and Lo HW: Mechanisms regulating glioma invasion. Cancer Lett.
362:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Giese A, Bjerkvig R, Berens ME and
Westphal M: Cost of migration: Invasion of malignant gliomas and
implications for treatment. J Clin Oncol. 21:1624–1636. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Laks DR, Visnyei K and Kornblum HI: Brain
tumor stem cells as therapeutic targets in models of glioma. Yonsei
Med J. 51:633–640. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Orang Valinezhad A, Safaralizadeh R and
Kazemzadeh-Bavili M: Mechanisms of miRNA-mediated gene regulation
from common downregulation to mRNA-specific upregulation. Int J
Genomics. 2014:9706072014.PubMed/NCBI
|
|
10
|
Luo W and Sehgal A: Regulation of
circadian behavioral output via a MicroRNA-JAK/STAT circuit. Cell.
148:765–779. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rachagani S, Macha MA, Menning MS, Dey P,
Pai P, Smith LM, Mo YY and Batra SK: Changes in microRNA (miRNA)
expression during pancreatic cancer development and progression in
a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model.
Oncotarget. 6:40295–40309. 2015.PubMed/NCBI
|
|
12
|
Bagnoli M, Canevari S, Califano D, Losito
S, Maio MD, Raspagliesi F, Carcangiu ML, Toffoli G, Cecchin E,
Sorio R, et al: Multicentre Italian Trials in Ovarian cancer (MITO)
translational group: Development and validation of a microRNA-based
signature (MiROvaR) to predict early relapse or progression of
epithelial ovarian cancer: A cohort study. Lancet Oncol.
17:1137–1146. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang L, Wang YL, Liu S, Zhang PP, Chen Z,
Liu M and Tang H: miR-181b promotes cell proliferation and reduces
apoptosis by repressing the expression of adenylyl cyclase 9 (AC9)
in cervical cancer cells. FEBS Lett. 588:124–130. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen Y, Gao DY and Huang L: In vivo
delivery of miRNAs for cancer therapy: Challenges and strategies.
Adv Drug Deliv Rev. 81:128–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao Y, Pang D, Wang C, Zhong S and Wang
S: MicroRNA-134 modulates glioma cell U251 proliferation and
invasion by targeting KRAS and suppressing the ERK pathway. Tumour
Biol. 37:11485–11493. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hong L, Ya-Wei L, Hai W, Qiang Z, Jun-Jie
L, Huang A, Song-Tao Q and Yun-Tao L: MiR-519a functions as a tumor
suppressor in glioma by targeting the oncogenic STAT3 pathway. J
Neurooncol. 128:35–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cui R, Guan Y, Sun C, Chen L, Bao Y, Li G,
Qiu B, Meng X, Pang C and Wang Y: A tumor-suppressive microRNA,
miR-504, inhibits cell proliferation and promotes apoptosis by
targeting FOXP1 in human glioma. Cancer Lett. 374:1–11. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang X, Ding H, Han Y, Sun D, Wang H and
Zhai XU: The significance of microRNA-184 on JAK2/STAT3 signaling
pathway in the formation mechanism of glioblastoma. Oncol Lett.
10:3510–3514. 2015.PubMed/NCBI
|
|
19
|
Li Y, Min D, Wang K, Yin S, Zheng H and
Liu L: MicroRNA-152 inhibits cell proliferation, migration and
invasion by directly targeting MAFB in nasopharyngeal carcinoma.
Mol Med Rep. 15:948–956. 2017.PubMed/NCBI
|
|
20
|
He YJ, Wu JZ, Ji MH, Ma T, Qiao EQ, Ma R
and Tang JH: miR-342 is associated with estrogen receptor-α
expression and response to tamoxifen in breast cancer. Exp Ther
Med. 5:813–818. 2013.PubMed/NCBI
|
|
21
|
Savad S, Mehdipour P, Miryounesi M,
Shirkoohi R, Fereidooni F, Mansouri F and Modarressi MH: Expression
analysis of MiR-21, MiR-205, and MiR-342 in breast cancer in Iran.
Asian Pac J Cancer Prev. 13:873–877. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cittelly DM, Das PM, Spoelstra NS,
Edgerton SM, Richer JK, Thor AD and Jones FE: Downregulation of
miR-342 is associated with tamoxifen resistant breast tumors. Mol
Cancer. 9:3172010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang H, Wu J, Meng X, Ying X, Zuo Y, Liu
R, Pan Z, Kang T and Huang W: MicroRNA-342 inhibits colorectal
cancer cell proliferation and invasion by directly targeting DNA
methyltransferase 1. Carcinogenesis. 32:1033–1042. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2 (−Delta Delta C (T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kesanakurti D, Chetty C, Maddirela
Rajasekhar D, Gujrati M and Rao JS: Functional cooperativity by
direct interaction between PAK4 and MMP-2 in the regulation of
anoikis resistance, migration and invasion in glioma. Cell Death
Dis. 3:e4452012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tyagi N, Bhardwaj A, Singh AP, McClellan
S, Carter JE and Singh S: p-21 activated kinase 4 promotes
proliferation and survival of pancreatic cancer cells through AKT-
and ERK-dependent activation of NF-κB pathway. Oncotarget.
5:8778–8789. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fu X, Feng J, Zeng D, Ding Y, Yu C and
Yang B: PAK4 confers cisplatin resistance in gastric cancer cells
via PI3K/Akt- and MEK/ERK-dependent pathways. Biosci Rep.
34:342014. View Article : Google Scholar
|
|
28
|
Yu G, Jia Z and Dou Z: miR-24-3p regulates
bladder cancer cell proliferation, migration, invasion and
autophagy by targeting DEDD. Oncol Rep. 37:1123–1131.
2017.PubMed/NCBI
|
|
29
|
Lee SW, Park KC, Kim JG, Moon SJ, Kang SB,
Lee DS, Sul HJ, Ji JS and Jeong HY: Dysregulation of
MicroRNA-196b-5p and MicroRNA-375 in Gastric Cancer. J Gastric
Cancer. 16:221–229. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ma YS, Wu TM, Lv ZW, Lu GX, Cong XL, Xie
RT, Yang HQ, Chang ZY, Sun R, Chai L, et al: High expression of
miR-105-1 positively correlates with clinical prognosis of
hepatocellular carcinoma by targeting oncogene NCOA1. Oncotarget.
8:11896–11905. 2017.PubMed/NCBI
|
|
31
|
Li Z, Li B, Niu L and Ge L: miR-592
functions as a tumor suppressor in human non-small cell lung cancer
by targeting SOX9. Oncol Rep. 37:297–304. 2017.PubMed/NCBI
|
|
32
|
Wei Y, Sun J and Li X: MicroRNA-215
enhances invasion and migration by targeting retinoblastoma tumor
suppressor gene 1 in high-grade glioma. Biotechnol Lett.
39:197–205. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee KT, Tan JK, Lam AK and Gan SY:
MicroRNAs serving as potential biomarkers and therapeutic targets
in nasopharyngeal carcinoma: A critical review. Crit Rev Oncol
Hematol. 103:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li G, Shen Q, Li C, Li D, Chen J and He M:
Identification of circulating MicroRNAs as novel potential
biomarkers for hepatocellular carcinoma detection: A systematic
review and meta-analysis. Clin Transl Oncol. 17:684–693. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao L and Zhang Y: miR-342-3p affects
hepatocellular carcinoma cell proliferation via regulating NF-κB
pathway. Biochem Biophys Res Commun. 457:370–377. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xie X, Liu H, Wang M, Ding F, Xiao H, Hu
F, Hu R and Mei J: miR-342-3p targets RAP2B to suppress
proliferation and invasion of non-small cell lung cancer cells.
Tumour Biol. 36:5031–5038. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li XR, Chu HJ, Lv T, Wang L, Kong SF and
Dai SZ: miR-342-3p suppresses proliferation, migration and invasion
by targeting FOXM1 in human cervical cancer. FEBS Lett.
588:3298–3307. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Weng W, Okugawa Y, Toden S, Toiyama Y,
Kusunoki M and Goel A: FOXM1 and FOXQ1 are promising prognostic
biomarkers and novel targets of tumor-suppressive miR-342 in human
colorectal cancer. Clin Cancer Res. 22:4947–4957. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bokoch GM: Biology of the p21-activated
kinases. Annu Rev Biochem. 72:743–781. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rane CK and Minden A: P21 activated
kinases: Structure, regulation, and functions. Small GTPases.
5:52014. View Article : Google Scholar
|
|
41
|
Menges CW, Sementino E, Talarchek J, Xu J,
Chernoff J, Peterson JR and Testa JR: Group I p21-activated kinases
(PAKs) promote tumor cell proliferation and survival through the
AKT1 and Raf-MAPK pathways. Mol Cancer Res. 10:1178–1188. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yeo D, He H, Baldwin GS and Nikfarjam M:
The role of p21-activated kinases in pancreatic cancer. Pancreas.
44:363–369. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Song B, Wang W, Zheng Y, Yang J and Xu Z:
P21-activated kinase 1 and 4 were associated with colorectal cancer
metastasis and infiltration. J Surg Res. 196:130–135. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kobayashi K, Inokuchi M, Takagi Y, Otsuki
S, Fujimori Y, Sato Y, Yanaka Y, Higuchi K, Aburatani T, Tomii C,
et al: Prognostic significance of PAK4 expression in gastric
cancer. J Clin Pathol. 69:580–585. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu W, Yang Y, Liu Y, Liu H, Zhang W, Xu
L, Zhu Y and Xu J: p21-Activated kinase 4 predicts early recurrence
and poor survival in patients with nonmetastatic clear cell renal
cell carcinoma. Urol Oncol. 33:205.e13–21. 2015. View Article : Google Scholar
|
|
46
|
Gnad F, Young A, Zhou W, Lyle K, Ong CC,
Stokes MP, Silva JC, Belvin M, Friedman LS, Koeppen H, et al:
Systems-wide analysis of K-Ras, Cdc42, and PAK4 signaling by
quantitative phosphoproteomics. Mol Cell Proteomics. 12:2070–2080.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dart AE and Wells CM: P21-activated kinase
4 - not just one of the PAK. Eur J Cell Biol. 92:129–138. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Siu MK, Chan HY, Kong DS, Wong ES, Wong
OG, Ngan HY, Tam KF, Zhang H, Li Z, Chan QK, et al: p21-activated
kinase 4 regulates ovarian cancer cell proliferation, migration,
and invasion and contributes to poor prognosis in patients. Proc
Natl Acad Sci USA. 107:18622–18627. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ahmed T, Shea K, Masters JR, Jones GE and
Wells CM: A PAK4-LIMK1 pathway drives prostate cancer cell
migration downstream of HGF. Cell Signal. 20:1320–1328. 2008.
View Article : Google Scholar : PubMed/NCBI
|
